Want to see RPID full AI Analyst Report?
RPID Stock Chart & Stats
$1.99
$0.00(0.00%)
At close: 4:00 PM EDT
$1.99
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.52 - $4.94
Previous CloseN/A
Volume24.17K
Average Volume (3M)253.56K
Market Cap
$84.27M
Enterprise Value$87.22
Total Cash (Recent Filing)$19.77M
Total Debt (Recent Filing)$23.48M
Price to Earnings (P/E)―
Beta1.14
Next Earnings
Nov 05, 2026EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.11
Shares Outstanding45,660,027
10 Day Avg. Volume146,703
30 Day Avg. Volume253,557
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)3.90
Price to Sales (P/S)3.86
P/FCF Ratio-4.06
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$6.67Price Target Upside235.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$39.33M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue And Installed Base GrowthGrowth in recurring revenue and validated systems supports a more durable business model, as consumables and services can compound after installation. Higher utilization may improve revenue visibility and customer retention over the next several quarters.
Strong Revenue And Consumables GrowthDouble-digit revenue growth, particularly in consumables, indicates increasing adoption of automated microbial testing and greater routine use of the platform. This strengthens the installed-base economics and supports management's target of more than 20% average annual growth.
Improving Gross And Service MarginsMaterial service-margin expansion and higher overall gross margin show progress in cost reduction, manufacturing efficiency and service productivity. If sustained as the installed base scales, these improvements could provide operating leverage and support the targeted 50% gross-margin exit by 2028.
Bears Say
Persistent Losses And Cash BurnLarge recurring operating losses and negative cash flow show that revenue growth has not yet translated into self-funding operations. Continued cash consumption could constrain investment, require external capital and delay the company's target of positive cash flow by 2028.
Rising Leverage And Financing DependenceHigher leverage alongside declining equity reduces financial flexibility while the company remains loss-making. Dependence on milestone-based debt and warrant proceeds creates execution and dilution risk, making future liquidity partly contingent on financing access and operational delivery.
Product Margin And Validation Ramp RiskNegative product margins indicate that system placements are not yet economically attractive on a standalone basis. The gap between total placements and validated systems also delays recurring consumable revenue, leaving profitability dependent on successful validation, utilization and cost improvements.
Rapid Micro Biosystems News
RPID FAQ
What was Rapid Micro Biosystems’s price range in the past 12 months?
Rapid Micro Biosystems lowest stock price was $1.52 and its highest was $4.94 in the past 12 months.
What is Rapid Micro Biosystems’s market cap?
Rapid Micro Biosystems’s market cap is $84.27M.
When is Rapid Micro Biosystems’s upcoming earnings report date?
Rapid Micro Biosystems’s upcoming earnings report date is Nov 05, 2026 which is in 74 days.
How were Rapid Micro Biosystems’s earnings last quarter?
Rapid Micro Biosystems released its earnings results on Aug 07, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.243 by -$0.027.
Is Rapid Micro Biosystems overvalued?
According to Wall Street analysts Rapid Micro Biosystems’s price is currently Undervalued.
Does Rapid Micro Biosystems pay dividends?
Rapid Micro Biosystems does not currently pay dividends.
What is Rapid Micro Biosystems’s EPS estimate?
Rapid Micro Biosystems’s EPS estimate is -0.2.
How many shares outstanding does Rapid Micro Biosystems have?
Rapid Micro Biosystems has 45,660,027 shares outstanding.
What happened to Rapid Micro Biosystems’s price movement after its last earnings report?
Rapid Micro Biosystems reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.243. Following the earnings report the stock price went down -16.827%.
Which hedge fund is a major shareholder of Rapid Micro Biosystems?
Currently, no hedge funds are holding shares in RPID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rapid Micro Biosystems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$6.67 (235.01% Upside)
$6.67 (235.01% Upside)
Hedge Fund Trend
Decreased
By 192.6K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
55.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-22.67%
Trailing 12-Months
Company Description
Rapid Micro Biosystems
Rapid Micro Biosystems, Inc. operates as a life sciences technology firm, supplying advanced solutions for identifying microbial impurities in the production processes of pharmaceuticals, medical devices, and personal care goods across North America, Europe, and Asia. Central to their offerings is the Growth Direct platform, a comprehensive system comprising the Growth Direct instrument, specialized disposable components, software for seamless integration with laboratory information management systems (LIMS), and extensive customer validation and support services. This innovative platform is designed to automate and modernize traditional, labor-intensive microbial quality control (MQC) testing workflows, which are critical for diverse therapeutic modalities such as biologics, vaccines, cutting-edge cell and gene therapies, and sterile injectable medications. Beyond their core product, the company also delivers essential services, including system installation, verification, expert technical training, and continuous support. Their technologies are widely applied in vital areas like environmental monitoring, water quality testing, bioburden assessment, and final sterility release evaluations. Established in 2006, the company initially traded as Genomic Profiling Systems, Inc., before rebranding to Rapid Micro Biosystems, Inc. in January 2007, and maintains its headquarters in Lowell, Massachusetts.
RPID Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed clear operational momentum: double-digit revenue growth (11% YoY), record consumable performance (>20% growth), a company milestone (200th system), a sizable increase in service margins (to 49%), and a pathway to improving gross margins through H2 2026 and longer-term targets (50% by end of 2028). At the same time, the company remains unprofitable with a Q2 net loss of $12.9M and adjusted EBITDA loss of $10.3M, product margins are still slightly negative, and liquidity depends on achieving debt milestone funding and potential warrant exercises. Overall, management emphasized improving fundamentals and execution while acknowledging remaining execution and financing risks.View all RPID earnings summariesRPID Stock 12 Month Forecast
Average Price Target
$6.67
▲(235.01% Upside)
Technical Analysis
Ownership Overview
32.78% Insiders
3.07% Mutual Funds
32.92% Other Institutional Investors
28.73% Public Companies and
Individual Investors